ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.465,69
-0,03%
S&P 500
5.180,74
1,03%
US Dollar vs BRL
5,0764
0,00%
Bitcoin
64.278,97
1,76%
Brent Oil
83,285
-0,23%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) Notícias

ITRM

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ITRM
DataHoraFonteTítuloCódigoCompanhia
06/05/202409:00GlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
29/04/202409:00GlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
28/03/202408:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ITRMIterum Therapeutics PLC
28/03/202408:00GlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
21/03/202417:30GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:ITRMIterum Therapeutics PLC
15/03/202409:00GlobeNewswire Inc.Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatNASDAQ:ITRMIterum Therapeutics PLC
06/03/202410:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
06/03/202410:00GlobeNewswire Inc.Iterum Therapeutics Provides Business UpdateNASDAQ:ITRMIterum Therapeutics PLC
30/01/202409:00PR Newswire (US)Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
14/12/202309:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
14/12/202309:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202319:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202319:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITRMIterum Therapeutics PLC
04/12/202310:00GlobeNewswire Inc.Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleNASDAQ:ITRMIterum Therapeutics PLC
07/11/202310:30GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:ITRMIterum Therapeutics PLC
24/10/202309:00GlobeNewswire Inc.Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
12/10/202310:15GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2023NASDAQ:ITRMIterum Therapeutics PLC
11/08/202308:00GlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
04/08/202318:00GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023NASDAQ:ITRMIterum Therapeutics PLC
15/06/202318:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITRMIterum Therapeutics PLC
12/06/202319:23GlobeNewswire Inc.Iterum Therapeutics to Present Data at ASM Microbe 2023NASDAQ:ITRMIterum Therapeutics PLC
12/06/202317:45Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ITRMIterum Therapeutics PLC
05/06/202309:00Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ITRMIterum Therapeutics PLC
02/06/202317:13Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202308:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202308:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITRMIterum Therapeutics PLC
12/05/202308:00GlobeNewswire Inc.Iterum Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
20/04/202318:00GlobeNewswire Inc.Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration TrialsNASDAQ:ITRMIterum Therapeutics PLC
13/04/202317:16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITRMIterum Therapeutics PLC
07/04/202313:15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ITRMIterum Therapeutics PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:ITRM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
MNPR3
MINUPAR ON
BOV
ENAT3
ENAUTA ON
BOV
PRIO3
PETRORIO ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
TELB4
TELEBRAS PN
BOV
COGN3
COGNA ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados